Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 6275987, 8 pages
https://doi.org/10.1155/2017/6275987
Research Article

Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

1Department of Microbiology, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina
2Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
3Department of Infectology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
4Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina

Correspondence should be addressed to Ivan Jovanovic

Received 29 December 2016; Revised 24 February 2017; Accepted 26 February 2017; Published 11 April 2017

Academic Editor: Giuseppe Murdaca

Copyright © 2017 Ruzica Lukic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Lanini, P. J. Easterbrook, A. Zumla, and G. Ippolito, “Hepatitis C: global epidemiology and strategies for control,” Clinical Microbiology and Infection, vol. 22, no. 10, pp. 833–838, 2016. View at Publisher · View at Google Scholar
  3. T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle, “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132, no. 4, pp. 296–305, 2000. View at Publisher · View at Google Scholar
  4. T. Kanto and N. Hayashi, “Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity,” Internal Medicine, vol. 45, no. 4, pp. 183–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. L. N. Elliot, A. R. Lloyd, J. B. Ziegler, and R. A. Ffrench, “Protective immunity against hepatitis C virus infection,” Immunology and Cell Biology, vol. 84, no. 3, pp. 239–249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Jha, G. Garcia-Garcia, K. Iseki et al., “Chronic kidney disease: global dimension and perspectives,” Lancet, vol. 382, no. 9888, pp. 260–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” Lancet, vol. 380, no. 9859, pp. 2095–2128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. K. Haroun, B. G. Jaar, S. C. Hoffman, G. W. Comstock, M. J. Klag, and J. Coresh, “Risk factors for chronic kidney disease: a prospective study of 23, 534 men and women in Washington County Maryland,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2934–2941, 2003. View at Google Scholar
  9. A. Ojo, “Addressing the global burden of chronic kidney disease through clinical and translational research,” Transactions of the American Clinical and Climatological Association, vol. 125, pp. 229–243, 2014, discussion 243-6 View at Google Scholar
  10. N. R. Hill, S. T. Fatoba, J. L. Oke et al., “Global prevalence of chronic kidney disease - a systematic review and meta-analysis,” PloS One, vol. 11, no. 7, article e0158765, 2016, eCollection 2016 View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Betjes, “Immune cell dysfunction and inflammation in end-stage renal disease,” Nature Reviews Nephrology, vol. 9, no. 5, pp. 255–265, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. D. Vaziri, M. V. Pahl, A. Crum, and K. Norris, “Effect of uremia on structure and function of immune system,” Journal of Renal Nutrition, vol. 22, no. 1, pp. 149–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi, “Hepatitis C infection and chronic renal diseases,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 207–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. N. Azmi, S. S. Tan, and R. Mohamed, “Hepatitis C and kidney disease: an overview and approach to management,” World Journal of Hepatology, vol. 7, no. 1, pp. 78–92, 2015. View at Google Scholar
  15. C. H. Liu and J. H. Kao, “Treatment of hepatitis C virus infection in patients with end-stage renal disease,” Journal of Gastroenterology and Hepatology, vol. 26, no. 2, pp. 228–239, 2011 Feb. View at Google Scholar
  16. D. Ozer Etik, S. Ocal, and A. S. Boyacioglu, “Hepatitis C infection in hemodialysis patients: a review,” World Journal of Hepatology, vol. 7, no. 6, pp. 885–895, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Fabrizi, F. F. Poordad, and P. Martin, “Hepatitis C infection and the patient with end-stage renal disease,” Hepatology, vol. 36, no. 1, pp. 3–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Marinaki, J. N. Boletis, S. Sakellariou, and I. K. Delladetsima, “Hepatitis C in hemodialysis patients,” World Journal of Hepatology, vol. 7, no. 3, pp. 548–558, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Okuda and O. Yokosuka, “Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up,” World Journal of Gastroenterology, vol. 10, no. 15, pp. 2209–2212, 2004. View at Google Scholar
  20. H. Ishida, T. Agishi, I. Koyama et al., “Hemodialysis paradox: survey on the incidence rate of hepatocellular carcinoma in antihepatitis virus C-antibody-positive chronic hemodialysis patients,” Artificial Organs, vol. 25, no. 1, pp. 58–60, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Breuilh, F. Vanhoutte, J. Fontaine et al., “Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells,” Infection and Immunity, vol. 75, no. 11, pp. 5148–5157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Ahmad, H. J. Gabius, S. André et al., “Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 10841–10847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Radosavljevic, I. Jovanovic, I. Majstorovic et al., “Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity,” Clinical & Experimental Metastasis, vol. 28, no. 5, pp. 451–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ulu, A. Alacacioglu, E. Yuksel et al., “Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis,” Saudi Journal of Gastroenterology, vol. 21, no. 1, pp. 47–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Desmedt, S. Desmedt, J. R. Delanghe, R. Speeckaert, and M. M. Speeckaert, “Galectin-3 in renal pathology: more than just an innocent bystander,” American Journal of Nephrology, vol. 43, no. 5, pp. 305–317, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Jovanovic, G. Radosavljevic, S. Pavlovic et al., “Th-17 cells as novel participant in immunity to breast cancer,” Serbian Journal of Experimental and Clinical Research, vol. 11, no. 1, pp. 59–65, 2010. View at Google Scholar
  27. H. Bantel and K. Schulze-Osthoff, “Apoptosis in hepatitis C virus infection,” Cell Death and Differentiation, vol. 10, Supplement 1, pp. S48–S58, 2003. View at Google Scholar
  28. T. Rampino, E. Arbustini, M. Gregorini et al., “Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor,” Kidney International, vol. 56, no. 6, pp. 2286–2291, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Assy and G. Y. Minuk, “Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults,” The American Journal of Gastroenterology, vol. 95, no. 6, pp. 1545–1550, 2000. View at Publisher · View at Google Scholar
  30. H. Vacher-Coponat, C. Brunet, L. Lyonnet et al., “Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients,” Nephrology, Dialysis, Transplantation, vol. 23, no. 4, pp. 1406–1414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Knerr, R. Füth, P. Hemsen et al., “Chronic inflammation and hemodialysis reduce immune competence of peripheral blood leukocytes in end-stage renal failure patients,” Cytokine, vol. 30, no. 3, pp. 132–138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Ruiz, F. Gomez, and A. D. Schreiber, “Impaired function of macrophage Fc gamma receptors in end-stage renal disease,” The New England Journal of Medicine, vol. 322, no. 11, pp. 717–722, 1990. View at Publisher · View at Google Scholar
  33. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews. Immunology, vol. 8, no. 5, pp. 337–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. D. R. Burton, “Antibodies, viruses and vaccines,” Nature Reviews. Immunology, vol. 2, no. 9, pp. 706–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Chen, N. Ghilardi, H. Wang et al., “Development of Th1-type immune responses requires the type I cytokine receptor TCCR,” Nature, vol. 407, no. 6806, pp. 916–920, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Eleftheriadis, G. Antoniadi, V. Liakopoulos, C. Kartsios, and I. Stefanidis, “Disturbances of acquired immunity in hemodialysis patients,” Seminars in Dialysis, vol. 20, no. 5, pp. 440–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Böhm, U. A. Köhler, T. Speicher, and S. Werner, “Regulation of liver regeneration by growth factors and cytokines,” EMBO Molecular Medicine, vol. 2, no. 8, pp. 294–305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Gao, “Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease,” Journal of Gastroenterology and Hepatology, vol. 27, no. Suppl 2, pp. 89–93, 2012. View at Google Scholar
  39. R. Taub, “Liver regeneration: from myth to mechanism,” Nature Reviews Molecular Cell Biology, vol. 5, no. 10, pp. 836–847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Teoh, J. Field, and G. Farrell, “Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice,” Journal of Hepatology, vol. 45, no. 1, pp. 20–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Scheller, A. Chalaris, D. Schmidt-Arras, and S. Rose-John, “The pro- and anti-inflammatory properties of the cytokine interleukin-6,” Biochimica et Biophysica Acta, vol. 1813, no. 5, pp. 878–888, 2011. View at Google Scholar
  42. E. J. Lim, K. El Khobar, R. Chin et al., “Hepatitis C virus-induced hepatocyte cell death and protection by inhibition of apoptosis,” The Journal of General Virology, vol. 95, no. Part 10, pp. 2204–2215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. B. K. Moon, Y. J. Lee, P. Battle, J. M. Jessup, A. Raz, and H. R. Kim, “Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis,” The American Journal of Pathology, vol. 159, no. 3, pp. 1055–1060, 2001. View at Publisher · View at Google Scholar
  44. T. A. Baptiste, A. James, M. Saria, and J. Ochieng, “Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin,” Experimental Cell Research, vol. 313, no. 4, pp. 652–664, 2007. View at Publisher · View at Google Scholar · View at Scopus